Abstract
The bone GLA protein (BGP) or osteocalcin, is a vitamin K-dependent protein produced by the osteoblasts (1), which accumulates in the non-collagenous protein fraction of bone, but it is also measurable by radioimmunoassay in the serum (2). In vitro (1) and experimental in vivo studies (3) have shown that production of this protein is modulated by 1,25(OH)2D3. However a basal production of BGP can be observed even in the vitamin D depleted animal (3). In predialysis chronic renal failure serum BGP levels are higher than normal (4) in spite of the known 1,25(OH)2D3 deficit (5).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J.N.Beresford, J.A.Gallagher, J.W. Poser and R.G.G. Russell, Production of osteocalcin by human bone cells in vitro. Effects of 1,25(OH)2D3, 24,25(OH)2D3, parathroid hormone and glucosteroids.Metab. Bone Dis. & Rel.Res. 5: 229 (1984).
P.A.Price and S.K.Nishimoto, Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc. Natl. Acad. Sci., USA 77: 2234 (1980).
P.A.Price, M.K.Williamson and S.A.Baukol, The vitamin K-dependent bone protein and the vitamin D-dependent biochemical response of bone to dietary calcium deficiency. In: Vitamin D, Chemical, Biochemical and Clinical Endocrinology of Calcium Metabolism. A.W.Norman et al. eds, W. de Gruyter, Berlin-New York, p. 351 (1982).
A.K.Cheung, S.C.Manolagas, B.D.Chaterwood, C.A.Mosely Jr., J.A.Mitas II, R.C.Blantz and L.J.Deftos, Determinants of serum 1,25(OH)2D3 levels in renal disease. Kidney Int. 24: 104 (1983).
E.B.Mawer, J.Backhouse, C.M.Taylor, G.A.Lumb and S.W.Stanbury, Failure of formation of 1,25dihydroxycholecalciferol in chronic renal insufficiency. Lancet 1: 626 (1973).
G.Coen, F.Messa, M.Donnetti, C.Massimetti, S.Mazzaferro, G.Donato, G. Giuliano, D.Finistauri and G.A.Cinotti, 1-alpha-0HD3 and low phosphate diet in predialysis chronic renal failure: effects on secondary hyperparathyroidism and on renal function. Acta Vitam.Enzym. 6: 129 (1984).
J.A.Eisman, A.J.Hamstra, B.E.Kream and H.F.DeLuca, 1,25-dihydroxyvitamin D in biological fluids: a simplified and sensitive assay. Science 193: 1021 (1976).
A.Smacchi, A.R.Bianchi, G.Donato, D.Palmiotti, B.Bacchielli, L.Chini and G.Coen, A simplified assay of 1,25dihydroxycholecalciferol in serum, Mineral Metab.Res. in Italy 4: 179 (1983).
G.Coen, S.Mazzaferro, E.Bonucci, F.Taggi, P.Ballanti, A.R.Bianchi, G.Donato, C.Massimetti, A.Smacchi and G.A.Cinotti, Bone GLA protein in predialysis chronic renal failure: effects of 1,25(OH)2D3 administration in a long-term follow-up, Kidney Int. (in press).
G.Coen, S.Mazzaferro, E.Bonucci, P.Ballanti, C.Massimetti, G.Donato, F.Bondatti, A.Smacchi, G.A.Cinotti and F.Taggi, Serum bone GLA protein (BGP) and secondary hyperparathyroidism in predialysis chronic renal failure. In: Vitamin D, Chemical, Biochemical and Clinical Update. A.W.Norman et al. eds, W. de Gruyter, Berlin-New York, p. 1147 (1985).
R.S.Weinstein and C.M.Gundberg, Multiple immunoreactive forms of osteocalcin in the sera of dialysis patients.(Abs) VIIth Annual Scientific Meeting, American Society for Bone and Mineral Research, June 15–18 (1985).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Coen, G. et al. (1986). Effects of 1,25(OH)2D3 Administration on Serum Bone GLA Protein in Predialysis Chronic Renal Failure. In: Massry, S.G., Olmer, M., Ritz, E. (eds) Phosphate and Mineral Homeostasis. Advances in Experimental Medicine and Biology, vol 208. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5206-8_38
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5206-8_38
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5208-2
Online ISBN: 978-1-4684-5206-8
eBook Packages: Springer Book Archive